Best of 2022: Did you watch this?

Alpesh's biggest Stock of the Week this year... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Note: Is edwardlorilla1986.paxforex@blogger.com your correct email? You haven't clicked in a while and we're concerned you might lose access. Please confirm your address with one click here. Stock of the Week: A Soaring Biotech With an Impressive 34% CROCI SPONSORED This secret indicator could be the key to turning tiny sums (starting stakes of less than $100) into SERIOUS cash windfalls. Financial Times Trading Champion and senior-most Dealmaker for the U.K.'s International Department of Trade reveals his exact strategy for every major investment decision he makes. Click the link now to see the full $1.1 billion success story! A Note From Amanda: This year, we launched Alpesh's popular video series Stock of the Week. In it, Alpesh gives you a taste of his award-winning stock-picking and hedge fund expertise. We sure hope you followed along... because the stocks Alpesh showed you could have netted you gains of 62%... 75%... and even 104%! All while the S&P has been down by double digits for much of the year. Today, we'd like to share the stock that's been the biggest success from the series this year. It's up an impressive 120%... and you'll see why in the video below. Be sure to tune in to Alpesh's videos in 2023... and become a subscriber to his GVI Investor research service, where you'll get exclusive recommendations backed by his hedge fund research. Click here for more details. Alpesh Patel Trading Champion There aren't many stocks that have gone up in 2022. But this one has... after nearly doubling last year. It's a biotechnology company that's addressing the huge and growing need to treat chronic diseases as our population ages. It's seen some big gains over the past few years... [Oh boy... Andy just went rogue (again!). He posted key info about his first pick of 2023... Click here to check it out.] But even better... it has an impressive 34% CROCI (cash return on capital invested). Find out which stock hits the mark for my Growth-Value-Income system this week... It's all in the latest episode of Stock of the Week. Click here or on the image below to watch it. GET THE STOCK Happy hunting, Alpesh P.S. New year, new tickers! Send the stocks you'd like me to review in a note to mailbag@manwardpress.com. And be sure to let me know how you're enjoying this series. SPONSORED "IMPERIUM": The #1 Investment of the 2020s Could the technology behind this odd-looking machine really be the most transformative innovation in history? Experts are screaming "YES"! Elon Musk calls it "amazing..." A former Apple CEO says "[it will] have a far bigger impact on humanity than the Internet"... While a Harvard Ph.D. says it will "[surpass] the space, atomic, and electronic revolutions in its significance." It's a technology I call "Imperium." And it's about to spark the biggest investment mega trend in history... with one small Silicon Valley company at the center of it all. Want the details? Then click here now...   Want more content like this? YES NO   Alpesh Patel | Trading Champion Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.   Was this email forwarded to you? Click here to sign up! You are receiving this email because you subscribed to Manward Financial Digest. To unsubscribe from Manward Financial Digest, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press, LLC | Attn: Support Team | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Manward Financial Digest. © 2021 Manward Press, LLC | All Rights Reserved Manward Press, LLC is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that investment markets have inherent risks and there can be no guarantee of future profits. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.